Researcher
Siel Olbrecht
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From16 Mar 2017 → 9 Aug 2021
Projects
1 - 1 of 1
- Comprehensive transcriptomic analysis of high-grade serous tubo-ovarian carcinoma using single-cell RNA-sequencing.From1 Mar 2017 → 5 Jul 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 13
- Systematic study of tissue factor expression in solid tumors(2023)
Authors: Siel Olbrecht, Ignace Vergote
- Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer(2022)
Authors: Pieter Busschaert, Siel Olbrecht, An Coosemans, Wouter Froyman, Liselore Loverix, Els Van Nieuwenhuysen, Sileny Han, Toon Van Gorp, Tom Venken, Ruben Heremans, et al.
- Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer(2022)
Authors: Liselore Loverix, Pieter Busschaert, Els Van Nieuwenhuysen, Sileny Han, Siel Olbrecht, Patrick Neven, Diether Lambrechts, Toon Van Gorp, Ignace Vergote
Pages: 14 - 22 - MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma(2022)
Authors: Diether Lambrechts, Liselore Loverix, Siel Olbrecht, Ignace Vergote
Pages: 855 - 871 - Polygenic risk modeling for prediction of epithelial ovarian cancer risk(2022)
Authors: Diether Lambrechts, Siel Olbrecht
Pages: 349 - 362 - High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification(2021)
Authors: Siel Olbrecht, Pieter Busschaert, Jun Qian, Liselore Loverix, Toon Van Gorp, Els Van Nieuwenhuysen, Sileny Han, An Coosemans, Anne-Sophie Van Rompuy, Diether Lambrechts, et al.
- Comprehensive transcriptomic analysis of high-grade serous tubo-ovarian carcinoma using single-cell RNA-sequencing.(2021)
Authors: Siel Olbrecht, Ignace Vergote, Diether Lambrechts
- Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial(2020)
Authors: A Vanderstichele, L Loverix, C De Vogelaere, L Heyrman, T Van Gorp, E Van Nieuwenhuysen, S Han, Siel Olbrecht, P Berteloot, P Neven, et al.
Pages: S617 - S618 - A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling(2020)
Authors: Siel Olbrecht, Bram Boeckx, Hanne Vos, H. Emre Etlioglu, Els Wauters, Sara Verbandt, Pieter Busschaert, Ayse Bassez, Amelie Franken, Jieyi Xiong, et al.
Pages: 745 - 762 - ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease(2019)
Authors: Ignace Vergote, Thaïs Baert, Siel Olbrecht
Pages: 728 - 760